Assignee
NYMOX CORP
BS·26 granted patents·6 pending applications·277 citations·filing 1997–2024
Top patents by PatentIndex Score
32 records- 0195US6942858B1Compositions containing bacteriophages and methods of using bacteriophages to treat infectionsNYMOX CORP·Filed 2000·Granted Sep 13, 2005·50 cites·12 claims
- 0294US9243035B2Peptides effective in the treatment of conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2013·Granted Jan 26, 2016·21 cites·13 claims
- 0392US8569446B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2012·Granted Oct 29, 2013·14 cites·6 claims
- 0488US6924266B2NTP-peptides and method for removal of tumorsNYMOX CORP·Filed 2002·Granted Aug 2, 2005·29 cites·7 claims
- 0587US7514407B2Spheron component peptides and pharmaceutical compositionsNYMOX CORP·Filed 2003·Granted Apr 7, 2009·27 cites·12 claims
- 0687US7270818B2Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of DMSNYMOX CORP·Filed 2002·Granted Sep 18, 2007·21 cites·1 claims
- 0787US7192929B2Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cellsNYMOX CORP·Filed 2002·Granted Mar 20, 2007·22 cites·5 claims
- 0882US10183058B2Method of preventing or reducing the progression of prostate cancerNYMOX CORP·Filed 2016·Granted Jan 22, 2019·2 cites·14 claims
- 0981US6600947B2Method of detecting amyloid-containing lesions by autofluorescenceNYMOX CORP·Filed 2001·Granted Jul 29, 2003·30 cites·47 claims
- 1080US2025049882A1Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating lutsNYMOX CORP·Filed 2024·Application pending·0 cites
- 1179US6472421B1Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitorNYMOX CORP·Filed 1998·Granted Oct 29, 2002·53 cites·22 claims
- 1275US12090191B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2021·Granted Sep 17, 2024·0 cites·14 claims
- 1373US12329802B2Focal treatment of prostate cancerNYMOX CORP·Filed 2022·Granted Jun 17, 2025·0 cites·11 claims
- 1466US11298400B2Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTSNYMOX CORP·Filed 2019·Granted Apr 12, 2022·0 cites·19 claims
- 1564US2024252516A1Combination bph therapy with fexapotide triflutate, a 5-ari, and an alpha blockerNYMOX CORP·Filed 2023·Application pending·0 cites
- 1663US11231421B2Methods of treating multifocal cancerNYMOX CORP·Filed 2019·Granted Jan 25, 2022·0 cites·11 claims
- 1760US11331374B2Focal treatment of prostate cancerNYMOX CORP·Filed 2019·Granted May 17, 2022·0 cites·9 claims
- 1860US10335453B2Compositions and methods for improving sexual functionNYMOX CORP·Filed 2017·Granted Jul 2, 2019·0 cites·14 claims
- 1958US6518314B1Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 2000·Granted Feb 11, 2003·1 cites·9 claims
- 2054US11278588B2Method of treating lower urinary tract symptoms with fexapotide triflutateNYMOX CORP·Filed 2019·Granted Mar 22, 2022·0 cites·16 claims
- 2154US2005260171A1Compositions containing bacteriophages and method of using bacteriophages to treat infectionsNYMOX CORP·Filed 2005·Application pending·0 cites
- 2253US2020360466A1Method of improving lower urinary tract symptomsNYMOX CORP·Filed 2019·Application pending·0 cites
- 2351US10835538B2Method of treating benign prostatic hyperlasia with antibioticsNYMOX CORP·Filed 2018·Granted Nov 17, 2020·0 cites·15 claims
- 2451US7544771B2Protein and its use in diagnosing Alzheimer's diseaseNYMOX CORP·Filed 2005·Granted Jun 9, 2009·0 cites·7 claims
- 2551US6130221APharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptionsNYMOX CORP·Filed 1997·Granted Oct 10, 2000·4 cites·9 claims
- 2649US7572450B2Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteinsNYMOX CORP·Filed 2002·Granted Aug 11, 2009·0 cites·2 claims
- 2746US11628202B2Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasiaNYMOX CORP·Filed 2015·Granted Apr 18, 2023·0 cites·6 claims
- 2846US10172910B2Method of preventing or reducing the incidence of acute urinary retentionNYMOX CORP·Filed 2016·Granted Jan 8, 2019·0 cites·11 claims
- 2945US2020061150A1Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual functionNYMOX CORP·Filed 2018·Application pending·0 cites
- 3042US6413940B1Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMSNYMOX CORP·Filed 1998·Granted Jul 2, 2002·3 cites·1 claims
- 3141US10532081B2Method of ameliorating or preventing the worsening or the progression of symptoms of BPHNYMOX CORP·Filed 2016·Granted Jan 14, 2020·0 cites·18 claims
- 3236US2016361380A1Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferationsNYMOX CORP·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →